

Marc Cohen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3732965/publications.pdf>

Version: 2024-02-01

110
papers

11,211
citations

201674

27
h-index

34986

98
g-index

112
all docs

112
docs citations

112
times ranked

10552
citing authors

#	ARTICLE	IF	CITATIONS
1	The TIMI Risk Score for Unstable Angina/Non-â€“ST Elevation MI. JAMA - Journal of the American Medical Association, 2000, 284, 835.	7.4	2,704
2	Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. New England Journal of Medicine, 2012, 366, 9-19.	27.0	1,681
3	Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. New England Journal of Medicine, 2015, 372, 1791-1800.	27.0	1,585
4	Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. New England Journal of Medicine, 2016, 375, 2423-2434.	27.0	1,265
5	Clopidogrel with or without Omeprazole in Coronary Artery Disease. New England Journal of Medicine, 2010, 363, 1909-1917.	27.0	1,019
6	Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19. JAMA Internal Medicine, 2021, 181, 1612.	5.1	326
7	Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. Journal of the American College of Cardiology, 2016, 67, 2719-2728.	2.8	303
8	Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-â€“TIMI 54. Journal of the American College of Cardiology, 2016, 67, 2732-2740.	2.8	179
9	An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). American Heart Journal, 2015, 169, 472-478.e5.	2.7	140
10	Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y₁₂inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. European Heart Journal, 2016, 37, 1133-1142.	2.2	138
11	Platelet Inhibition With Ticagrelor 60-â€“mg-â€“Versus 90 mg Twice Daily in the-â€“PEGASUS-TIMI 54 Trial. Journal of the American College of Cardiology, 2016, 67, 1145-1154.	2.8	108
12	Randomized, Double-Blind, Dose-Ranging Study of Otamixaban, a Novel, Parenteral, Short-Acting Direct Factor Xa Inhibitor, in Percutaneous Coronary Intervention. Circulation, 2007, 115, 2642-2651.	1.6	96
13	Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-â€“Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. American Heart Journal, 2014, 167, 437-444.e5.	2.7	89
14	Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events. JAMA Cardiology, 2016, 1, 425.	6.1	88
15	Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy. Circulation, 2017, 135, 323-333.	1.6	86
16	The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI). Journal of the American College of Cardiology, 2003, 42, 1348-1356.	2.8	80
17	A Subgroup Analysis of the Impact of Prerandomization Antithrombin Therapy on Outcomes in the SYNERGY Trial. Journal of the American College of Cardiology, 2006, 48, 1346-1354.	2.8	79
18	Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. European Heart Journal, 2016, 37, ehv482.	2.2	70

#	ARTICLE	IF	CITATIONS
19	Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1661-1671.	2.8	69
20	Coronavirus disease 19 in minority populations of Newark, New Jersey. <i>International Journal for Equity in Health</i> , 2020, 19, 93.	3.5	51
21	Therapy for ST-Segment Elevation Myocardial Infarction Patients Who Present Late or Are Ineligible for Reperfusion Therapy. <i>Journal of the American College of Cardiology</i> , 2010, 55, 1895-1906.	2.8	47
22	Prospective Evaluation of Clinical Outcomes After Acute ST-Elevation Myocardial Infarction in Patients Who Are Ineligible for Reperfusion Therapy: Preliminary Results From the TETAMI Registry and Randomized Trial. <i>Circulation</i> , 2003, 108, 1411-21.	1.6	41
23	Quantitative increase in frailty is associated with diminished survival after transcatheter aortic valve replacement. <i>American Heart Journal</i> , 2016, 182, 146-154.	2.7	40
24	Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction. <i>Circulation</i> , 2016, 134, 861-871.	1.6	40
25	Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial. <i>American Journal of Medicine</i> , 2016, 129, 1002-1005.	1.5	32
26	Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. <i>Circulation</i> , 2021, 143, 470-478.	1.6	32
27	Timing of Angiography and Outcomes in High-Risk Patients With Non-ST-Segment Elevation Myocardial Infarction Managed Invasively. <i>Circulation</i> , 2017, 136, 1895-1907.	1.6	29
28	CT Angiography Analysis of Axillary Artery Diameter versus Common Femoral Artery Diameter: Implications for Axillary Approach for Transcatheter Aortic Valve Replacement in Patients with Hostile Aortoiliac Segment and Advanced Lung Disease. <i>International Journal of Vascular Medicine</i> , 2016, 2016, 1-5.	1.0	28
29	The role of low-molecular-weight heparin in the management of acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , 2003, 41, S55-S61.	2.8	27
30	Pathophysiology and Disease Progression of Atrial Fibrillation: Importance of Achieving and Maintaining Sinus Rhythm. <i>Journal of Cardiovascular Electrophysiology</i> , 2008, 19, 885-890.	1.7	27
31	Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines. <i>JAMA Cardiology</i> , 2020, 5, 1255.	6.1	27
32	The Role of Gender and Other Factors as Predictors of Not Receiving Reperfusion Therapy and of Outcome in ST-Segment Elevation Myocardial Infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2005, 19, 155-161.	2.1	26
33	Antiplatelet therapy in percutaneous coronary intervention: A critical review of the 2007 AHA/ACC/SCAI guidelines and beyond. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 74, 579-597.	1.7	26
34	Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 626-634.	2.9	25
35	Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 200-206.	3.0	25
36	Routine Invasive Versus Selective Invasive Strategy in Elderly Patients Older Than 75 Years With Non-ST-Segment Elevation Acute Coronary Syndrome: A Systematic Review and Meta-Analysis. <i>Mayo Clinic Proceedings</i> , 2018, 93, 436-444.	3.0	24

#	ARTICLE	IF	CITATIONS
37	Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2017, 70, 527-538.	2.8	23
38	Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis. <i>Circulation</i> , 2018, 137, 684-692.	1.6	22
39	Meta-Analysis of Randomized Controlled Trials of Percutaneous Coronary Intervention With Drug-Eluting Stents Versus Coronary Artery Bypass Grafting in Left Main Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2017, 119, 1942-1948.	1.6	21
40	Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Thrombosis: Phlegmasia Cerulea Dolens Presenting with Venous Gangrene in a Child. <i>Journal of Pediatrics</i> , 2020, 226, 281-284.e1.	1.8	20
41	Differential responses to larger volume intra-aortic balloon counterpulsation: Hemodynamic and clinical outcomes. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 703-710.	1.7	19
42	Temporal Trends, Predictors, and Outcomes of Acute Ischemic Stroke in Acute Myocardial Infarction in the United States. <i>Journal of the American Heart Association</i> , 2021, 10, e017693.	3.7	19
43	Long-term outcomes in high-risk patients with non-ST-segment elevation myocardial infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 464-474.	2.1	18
44	Implications of Misclassification of Type 2 Myocardial Infarction on Clinical Outcomes. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 176-179.	0.8	18
45	Defining and managing patients with non-ST-segment elevation myocardial infarction: Sorting through type 1 vs other types. <i>Clinical Cardiology</i> , 2020, 43, 242-250.	1.8	18
46	Usefulness of Rivaroxaban for Secondary Prevention of Acute Coronary Syndrome in Patients With History of Congestive Heart Failure (from the ATLAS-ACS-2 TIMI-51 Trial). <i>American Journal of Cardiology</i> , 2018, 122, 1896-1901.	1.6	17
47	Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2021, 10, e017008.	3.7	17
48	Effects of Prone Ventilation on Oxygenation, Inflammation, and Lung Infiltrates in COVID-19 Related Acute Respiratory Distress Syndrome: A Retrospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 4129.	2.4	16
49	Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTEMI: A subgroup analysis from the SYNERGY trial. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 928-935.	1.7	15
50	Emergent TandemHeart-ECMO for acute severe mitral regurgitation with cardiogenic shock and hypoxaemia: a case series. <i>European Heart Journal - Case Reports</i> , 2020, 4, 1-6.	0.6	15
51	Cardiac troponin and outcome in decompensated heart failure with preserved ejection fraction. <i>Cardiovascular Diagnosis and Therapy</i> , 2017, 7, 359-366.	1.7	14
52	Recurrent Stroke Reduction with Patent Foramen Ovale Closure versus Medical Therapy Based on Patent Foramen Ovale Characteristics: A Meta-Analysis of Randomized Controlled Trials. <i>Cardiology</i> , 2019, 144, 40-49.	1.4	14
53	A single center tertiary care experience utilizing the large volume mega 50cc intra-aortic balloon counterpulsation in contemporary clinical practice. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, E63-E72.	1.7	11
54	Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007124.	3.9	11

#	ARTICLE	IF	CITATIONS
55	Pharmacoinvasive management of acute coronary syndrome: incorporating the 2007 ACC/AHA guidelines: the CATH (cardiac catheterization and antithrombotic therapy in the hospital) Clinical Consensus Panel Report–III. <i>Journal of Invasive Cardiology</i> , 2007, 19, 525-38; quiz 539-40.	0.4	11
56	US Food and Drug Administration approval of generic versions of complex biologics: implications for the practicing physician using low molecular weight heparins. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 33, 230-238.	2.1	10
57	The “Dual” Pathway Strategy after Acute Coronary Syndrome: Rivaroxaban and Antiplatelet Agents in the ATLAS ACS 2-TIMI 51 Trial. <i>Cardiovascular Therapeutics</i> , 2014, 32, 224-232.	2.5	10
58	Intravenous Enoxaparin Versus Unfractionated Heparin in Elderly Patients Undergoing Primary Percutaneous Coronary Intervention. <i>Angiology</i> , 2017, 68, 29-39.	1.8	10
59	Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 346-350.	2.1	10
60	Safety and efficacy of non-vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial. <i>American Heart Journal</i> , 2018, 203, 17-24.	2.7	10
61	The evolution of thrombolytic therapy and adjunctive antithrombotic regimens in acute ST-segment elevation myocardial infarction. <i>American Journal of Emergency Medicine</i> , 2004, 22, 14-23.	1.6	9
62	Aortico-Left Atrial Fistula: A Rare Complication of Bioprosthetic Aortic Valve Endocarditis Secondary to <i>Enterococcus faecalis</i> . <i>Case Reports in Cardiology</i> , 2015, 2015, 1-4.	0.2	9
63	Incidence and consequence of major bleeding in primary percutaneous intervention for ST-elevation myocardial infarction in the era of radial access: an analysis of the international randomized Acute myocardial infarction Treated with primary angioplasty and intravenous enoxaparin Or unfractionated heparin to Lower ischemic and bleeding events at short- and Long-term follow-up trial. <i>American Heart Journal</i> , 2015, 170, 778-786.	2.7	9
64	Contemporary NSTEMI management: the role of the hospitalist. <i>Hospital Practice (1995)</i> , 2020, 48, 1-11.	1.0	9
65	The Influence of Prior Oral Anticoagulation Therapy on the Anticoagulant Effect of Low Molecular Weight Heparin.. <i>Blood</i> , 2004, 104, 4080-4080.	1.4	9
66	Bleeding after antithrombotic therapy in patients with acute ischemic heart disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2008, 26, 175-182.	2.1	8
67	Percutaneous transaxillary approach for peripheral endovascular interventions. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 243-248.	1.7	8
68	Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006084.	3.9	7
69	Safety and efficacy of antiplatelet regimens after percutaneous coronary intervention using drug eluting stents: A network meta-analysis of randomized controlled trials. <i>Progress in Cardiovascular Diseases</i> , 2020, 63, 243-248.	3.1	7
70	Sex Differences in Ischemic and Bleeding Outcomes in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e009759.	3.9	7
71	Treatment-Dose LMWH versus Prophylactic/Intermediate Dose Heparins in High-Risk COVID-19 Inpatients: Rationale and Design of the HEP-COVID Trial. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1684-1695.	3.4	7
72	Oral Antiplatelet Therapy for Acute and Chronic Management of NSTEMI ACS: Residual Ischemic Risk and Opportunities for Improvement. <i>Cardiovascular Drugs and Therapy</i> , 2009, 23, 489-499.	2.6	6

#	ARTICLE	IF	CITATIONS
73	Re-evaluating risk factors for periprocedural complications during percutaneous coronary intervention in patients with unstable angina/non-ST-elevation myocardial infarction: who may benefit from more intensive antiplatelet therapy?. <i>Current Opinion in Cardiology</i> , 2009, 24, 88-94.	1.8	6
74	The Management of Patients with Atrial Fibrillation and Dronedarone's Place in Therapy. <i>Advances in Therapy</i> , 2011, 28, 1059-1077.	2.9	6
75	Cost Implications of Anticoagulation Strategies After Percutaneous Coronary Intervention Among Patients With Atrial Fibrillation (A PIONEER-AF PCI Analysis). <i>American Journal of Cardiology</i> , 2019, 123, 355-360.	1.6	6
76	Prioritizing elective cardiovascular procedures during the COVID-19 pandemic: The cardiovascular medically necessary, time-sensitive procedure scorecard. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, E602-E607.	1.7	6
77	Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e003006.	3.6	6
78	High-risk Acute Coronary Syndrome Patients with Non-ST-Elevation Myocardial Infarction: Definition and Treatment. <i>Cardiovascular Drugs and Therapy</i> , 2008, 22, 407-418.	2.6	5
79	The Thrombin Hypothesis in ACS: A Disappointing Disconnect between Bench Data and Bedside Clinical Trials. <i>American Journal of Medicine</i> , 2010, 123, 103-110.	1.5	5
80	Impact of Non-Infarct-Related Artery Disease on Infarct Size and Outcomes (from the CRISP-AMI Trial). <i>American Journal of Medicine</i> , 2016, 129, 1307-1315.	1.5	5
81	Prevalence, clinical determinants and prognostic implications of coronary procedural complications of percutaneous coronary intervention in non-ST-segment elevation myocardial infarction: Insights from the contemporary multinational TAO trial. <i>Archives of Cardiovascular Diseases</i> , 2021, 114, 187-196.	1.6	5
82	Expanding the recognition and assessment of bleeding events associated with antiplatelet therapy in primary care. <i>Mayo Clinic Proceedings</i> , 2009, 84, 149-60.	3.0	5
83	Impact of Tricuspid Valve Regurgitation on Early Outcomes after Transcatheter Aortic Valve Replacement. <i>Journal of Heart Valve Disease</i> , 2017, 26, 380-385.	0.5	5
84	Improving Long-Term ACS Management: Is There a Role for the New Antiplatelets?. <i>Journal of Interventional Cardiology</i> , 2012, 25, 425-432.	1.2	4
85	Ubiquitous Nature of Distal Athero/Thromboembolic Events during Lower Extremity Atherectomy Procedures Involving the Superficial Femoral Artery. <i>International Journal of Angiology</i> , 2016, 25, 252-257.	0.6	4
86	Pathogenesis of Coronary Occlusion. <i>Hospital Practice (1995)</i> , 1988, 23, 87-99.	1.0	3
87	Clinical characteristics and outcomes after unplanned intraaortic balloon counterpulsation in the Counterpulsation to Reduce Infarct Size Pre-PCI Acute Myocardial Infarction trial. <i>American Heart Journal</i> , 2016, 174, 7-13.	2.7	3
88	Biliary Disease in Immunocompromised Patients: a Single-Center Retrospective Analysis. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 1589-1592.	1.7	3
89	Eccentric hypertrophy predicts adverse events in patients undergoing percutaneous coronary intervention for acute coronary syndrome. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , 2021, 6, 21-27.	1.0	3
90	Treatment Strategies in Non-ST-Elevation Acute Coronary Syndromes in Patients Undergoing Percutaneous Coronary Intervention: An Evidence-Based Review of Clinical Trial Results and Treatment Guidelines: Report on a Roundtable Discussion. <i>Journal of Interventional Cardiology</i> , 2008, 21, 283-299.	1.2	2

#	ARTICLE	IF	CITATIONS
91	Acute left ventricular dysfunction complicating pregnancy on ECMO: Tri-iodothyronine to the rescue with real time transesophageal echocardiography. <i>Journal of Cardiology Cases</i> , 2016, 13, 33-36.	0.5	2
92	Takeoff orientation of the major aortic arch branches irrespective of arch type: Ramifications for brachiocephalic interventions including carotid stenting. <i>SAGE Open Medicine</i> , 2018, 6, 205031211877671.	1.8	2
93	Size of Anterior Wall Acute Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention in United States Versus Europe/Australia Versus India (from the CRISP-AMI Randomized) <i>Tj ETQq1 1 0.784314 rgBT /Over</i>	0.784314	0
94	The use of adjunctive anticoagulants in patients with acute coronary syndrome transitioning to percutaneous coronary intervention. <i>American Journal of Emergency Medicine</i> , 2008, 26, 932-941.	1.6	1
95	Poorly recognized age-related downward deviation of the inguinal ligament. <i>SAGE Open Medicine</i> , 2016, 4, 205031211667556.	1.8	1
96	Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008160.	3.9	1
97	ST-elevation myocardial infarction in a young patient with anomalous right coronary artery and COVID-19 pneumonia. <i>European Heart Journal - Case Reports</i> , 2020, 4, 1-2.	0.6	1
98	Residual Shunt After Patent Foramen Ovale Closure and Long-Term Stroke Recurrence. <i>Annals of Internal Medicine</i> , 2020, 173, 945.	3.9	1
99	Antiplatelet therapy versus other antithrombotic strategies. , 2001, , 367-385.		0
100	At six months, enoxaparin is more effective than tinzaparin for people with non ST-segment elevation acute coronary syndromes. <i>Evidence-based Cardiovascular Medicine</i> , 2006, 10, 30-31.	0.0	0
101	Antiplatelet Effects of Thrombin Inhibitors and Fibrinolytic Agents. , 0, , 125-142.		0
102	Jetstream atherectomy and balloon angioplasty with distal embolic protection for Angio-Seal-related vascular access complications. <i>Cardiovascular Intervention and Therapeutics</i> , 2018, 33, 264-269.	2.3	0
103	The Utility of Echocardiography for Non-ST-Segment Elevation Myocardial Infarction: A Retrospective Study. <i>Journal of Diagnostic Medical Sonography</i> , 2020, 36, 121-129.	0.3	0
104	DAPT Duration: When Less Is More. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 1507-1508.	0.8	0
105	The effect of cardiac geometry variation according to sex and race on outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , 2021, 6, 152-159.	1.0	0
106	405 The Effect of a Patient Survey in the Evaluation of Obstructive Sleep Apnea in a High Risk Cardiology Outpatient Population. <i>Sleep</i> , 2021, 44, A161-A161.	1.1	0
107	STEMI in the Age of COVID: Unmasking Our Weaknesses. Is It the Virus That Matters?. <i>Cardiovascular Revascularization Medicine</i> , 2021, 30, 38-39.	0.8	0
108	The Role of Serial Testing for Heparin/PF4 Antibodies in Evolving HIT: A Unique Phenomenon of Delayed Seroconversion with Thrombosis.. <i>Blood</i> , 2007, 110, 1309-1309.	1.4	0

#	ARTICLE	IF	CITATIONS
109	Coronary artery bypass grafting versus percutaneous coronary intervention in complex coronary artery disease: looking beyond clinical end-points. <i>Annals of Translational Medicine</i> , 2017, 5, 491-491.	1.7	0
110	Where are we with vascular closure devices after percutaneous arteriotomy?. <i>Journal of Invasive Cardiology</i> , 2015, 27, 136-7.	0.4	0